Detalles de la búsqueda
1.
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma.
Mol Cancer
; 21(1): 20, 2022 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35042524
2.
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma.
J Transl Med
; 20(1): 159, 2022 04 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35382857
3.
BRAFV600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy.
Pharmacol Res
; 182: 106323, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35752358
4.
Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanoma.
J Transl Med
; 18(1): 473, 2020 12 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33302981
5.
Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors.
Acta Derm Venereol
; 100(1): adv00001, 2020 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31532537
6.
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.
Cancer Immunol Immunother
; 68(1): 97-107, 2019 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-30311027
7.
Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatment.
J Transl Med
; 17(1): 315, 2019 Sep 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-31533733
8.
Translational control mechanisms in cutaneous malignant melanoma: the role of eIF2α.
J Transl Med
; 17(1): 20, 2019 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30634982
9.
New paradigm for stage III melanoma: from surgery to adjuvant treatment.
J Transl Med
; 17(1): 266, 2019 08 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-31412885
10.
The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
BMC Cancer
; 18(1): 552, 2018 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29747595
11.
New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations.
Biochim Biophys Acta
; 1863(11): 2710-2718, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27542908
12.
Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
BMC Cancer
; 16(1): 905, 2016 11 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-27863476
13.
Local treatment with electrochemotherapy of superficial angiosarcomas: Efficacy and safety results from a multi-institutional retrospective study.
J Surg Oncol
; 114(2): 246-53, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27156580
14.
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.
J Transl Med
; 13: 26, 2015 Jan 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-25623468
15.
Irradiation-induced angiosarcoma and anti-angiogenic therapy: a therapeutic hope?
Exp Cell Res
; 321(2): 240-7, 2014 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24384475
16.
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.
J Transl Med
; 12: 116, 2014 May 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-24885479
17.
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program.
Cancer Invest
; 32(4): 144-9, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24484235
18.
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases.
J Neurooncol
; 118(1): 109-16, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24532241
19.
Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?
Front Immunol
; 15: 1369531, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38799429
20.
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial.
Eur J Cancer
; 199: 113531, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38271746